OraSure Technologies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by OraSure Technologies, Inc. on September 17, 2021, with the earliest event reported on the same date. The filing discloses a significant regulatory and funding development regarding the Company's COVID-19 testing portfolio.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for a specific reporting period. The primary financial disclosure is a funding agreement.
- Funding Amount: Up to $13.6 million.
- Funding Source: Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS).
Material Changes and Events
On September 17, 2021, the Company entered into an agreement with BARDA. The funding is designated to support the Company in obtaining:
- 510(k) clearance from the U.S. Food and Drug Administration (FDA).
- Clinical Laboratory Improvement Amendments (CLIA) waiver.
The specific product targeted for these regulatory approvals is the InteliSwab® COVID-19 rapid test. A press release detailing this agreement was issued on September 23, 2021.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future earnings. The document includes standard disclaimers stating that the information is not deemed "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934 and that the Company undertakes no obligation to update the information publicly.
Key Facts for Investor Verification
- Verify the specific terms and milestones of the $13.6 million BARDA funding agreement.
- Confirm the current regulatory status of the InteliSwab® COVID-19 rapid test with the FDA.
- Review the attached press release (Exhibit 99.1) for details on the utilization of funds.
- Monitor future filings for updates on the 510(k) clearance and CLIA waiver status.